Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2010

Open Access 01-12-2010 | Review

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Authors: Xiongpeng Zhu, Yuehua Ma, Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2010

Login to get access

Abstract

Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia (AML). However, the long-term survival of AML with unfavorable factors remains unsatisfactory. The latest data indicate that the standard dose of daunorubicin (DNR) at 45 mg/m2 is inferior to high dose 90 mg/m2 for induction therapy. The rates of complete remission and overall survival are significantly better in the high dose induction regimen. New regimens exploring the new liposomal encapsulation of Ara-C and DNR as well as addition of gemtuzumab ozogamicin monoclonal antibody have been studied. New agents, including the nucleoside analogues (clofarabine, sapacitabine, elacytarabine), FLT3 inhibitor (sorafenib), farnesyl-transferase inhibitor (tipifarnib), histone deacetylase inhibitor (vorinostat), lenalidomide, as well as DNA methyltransferase inhibitors (decitabine, azacitidine), were recently reported for AML treatment in the 2009 ASH annual meeting. This review also summarizes the updates of the clinical trials on novel agents including voreloxin, AS1413, behenoylara-C, ARRY520, ribavirin, AZD1152, AZD6244, and terameprocol (EM-1421) from the 2009 ASH annual meeting.
Literature
1.
Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S: A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991, 78: 2520-2526.PubMed
2.
Larson RA: Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?. Leukemia. 2003, 17: 488-491. 10.1038/sj.leu.2402809.CrossRefPubMed
3.
Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL: Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004, 22: 4290-4301. 10.1200/JCO.2004.11.106.CrossRefPubMed
4.
Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S: Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. J Clin Oncol. 2010, 28: 808-814. 10.1200/JCO.2009.23.2652.CrossRefPubMed
5.
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009, 361: 1249-1259. 10.1056/NEJMoa0904544.PubMedCentralCrossRefPubMed
6.
Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009, 361: 1235-1248. 10.1056/NEJMoa0901409.CrossRefPubMed
7.
Rowe JM: Optimal induction and post-remission therapy for AML in first remission. Hematology. 2009, 2009: 396-405. 10.1182/asheducation-2009.1.396.CrossRef
8.
Feldman EJ, Lancet J, Kolitz JE, Ritchie E, List AF, Asatiani E: Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias. Blood. 2008, 112: abstract no. 2984.
9.
Lancet JE, Feldman E, Kolitz J, Tallman M, Hogge D, Komrokji R: Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report. Blood. 2009, 114: Abstract No1033-
10.
Kell WJ, Burnett AK, Chopra R, Yin JAL, Clark RE, Rohatiner A: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003, 102: 4277-4283. 10.1182/blood-2003-05-1620.CrossRefPubMed
11.
Burnett AK, Kell W, Goldstone AH: The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial. Blood. 2006, 108: Abstract No. 13.
12.
Borthakur G, Faderl S, Verstovsek S, Jones D, Gandhi V, Estrov Z: Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin. Blood. 2009, 114: Abstract No.2056.
13.
Paolini S, Parisi S, Candoni A, Piccaluga PP, Gottardi M, Laterza C: Four Drugs Induction Therapy (fludarabine, cytarabine, idarubicin and gemtuzumab ozogamycin) for the Treatment of Elderly Acute Myeloid Leukemia Patients. Blood. 2009, 114: Abstract No.1027.
14.
Larson S, Campbell N, Huo D, Artz A, Zhang Y, Gajria D: High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia. Blood. 2009, 114: Abstract No.1048.
15.
Miyawaki S, Hatsumi N, Yamauchi T: Phase 2 Study of FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report From the Japan Adult Leukemia Study Group (JALSG). Blood. 2009, 114: Abstract No.1058.
16.
Prébet T, Charbonnier A, Etienne A, D'Incan E, Fürst S, Blaise D: A Direct Comparison of High Dose Cytarabineto Combination of Gemtuzumab and High Dose Cytarabine for Acute Myeloid Leukemia Patients in First Relapse Confirmed the Benefit of Gemtuzumab Based Regimens. Blood. 2009, 114: Abstract No.2051.
17.
Scappini B, Gianfaldoni G, Salvatore P, Susini M, Izzo T, Mannelli F: High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients. Blood. 2009, 114: Abstract No.1060.
18.
Erba HP, Faderl S, Claxton D, Arellano M, Lyons R, Kovacsovics T: Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are = 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors. Blood. 2009, 114: Abstract No.2083.
19.
Becker PS, Estey E, Petersdorf S, Storer B, Appelbaum F: G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood. 2009, 114: 10.1182/blood-2009-02-206730. Abstract No.2068.
20.
Foster MC, Amin C, Voorhees P, Van Deventer H, Richards K, Anastasia I: A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML). Blood. 2009, 114: Abstract No.2048.
21.
Parikh SA, Hagop K, Garcia-Manero G, Jabbour E, Kadia T, Ravandi F: Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) = 60 Years (yrs). Blood. 2009, 114: Abstract No.2058.
22.
Kantarjian HM, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M: A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. Blood. 2009, 114: Abstract No.1061.
23.
O'Brien S, Rizzieri D, Vey N, Ravandi F, Krug U, Sekeres M: APhase II Multicentre Study with Elacytarabine as Second Salvage Therapyin Patients with AML. Blood. 2009, 114: Abstract No.1042.
24.
Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W: Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009, 2: 23-10.1186/1756-8722-2-23.PubMedCentralCrossRefPubMed
25.
Metzelder S, Scholl S, Matthias K, Reiter A, Meyer R, Heinicke T: Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia. Blood. 2009, 114: Abstract No.2060.
26.
Pemmaraju N, Kantarjian H, Ravandi F, Garcia-Manero G, Gautam B, Parikh S: FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status. Blood. 2009, 114: Abstract No. 1026.
27.
Schroeder T, Saure C, Bruns I, Zohren F, Czibere A, Safaian N: Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations. Blood. 2009, 114: Abstract No.2057.
28.
Al-Kali A, Jones D, Cortes J, Faderl S, Xue A, Garcia-Manero G: Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML). Blood. 2009, 114: Abstract No.2079.
29.
Baum K, Ren R: Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis. Journal of Hematology & Oncology. 2008, 1: 5-10.1186/1756-8722-1-5.CrossRef
30.
Paolini S, Ottaviani E, Parisi S, Salmi F, Lama B, Curti A: RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination. Blood. 2009, 114: Abstract No.1028.
31.
Feldman EJ, Ritchie E, Gergis U, Mayer S, Scandura J, Christos P: Evaluation of Alternative, "Low-intensity" Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML). Blood. 2009, 114: Abstract No.2066.
32.
Cang S, Ma Y, Liu D: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol. 2009, 2: 22-10.1186/1756-8722-2-22.PubMedCentralCrossRefPubMed
33.
Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM: Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009, 2: 31-10.1186/1756-8722-2-31.PubMedCentralCrossRefPubMed
34.
Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186/1756-8722-3-5.PubMedCentralCrossRefPubMed
35.
Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM: Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor 2. Blood. 2006, 108: 1174-1182. 10.1182/blood-2005-09-008086.PubMedCentralCrossRefPubMed
36.
Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias 1. Clin Cancer Res. 2009, 15: 1698-1707. 10.1158/1078-0432.CCR-08-1587.CrossRefPubMed
37.
Garcia-Manero G, Tambaro P F, Bekele N, Jabbour E, Ravandi F, Yang H: Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). Blood. 2009, 114: Abstract No.1055.
38.
Kirschbaum M, Ivana G, Goldberg S, Kujawski L, Atallah E, Marks P: Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study. Blood. 2009, 114: Abstract No.2089.
39.
Borthakur G, Garcia-Manero G, Estrov Z, Konopleva M, Burger J, Thomas De: Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome-Outcome in Previously Untreated Patients. Blood. 2009, 114: Abstract No.1053.
40.
Ritchie EK, Arnason J, Feldman E, Gergis U, Mayer S, Ippoliti C: Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia. Blood. 2009, 114: Abstract No.2063.
41.
Itzykson R, Thepo S, Reche C, Delaunay J, Quesnel B: Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program. Blood. 2009, 114: Abstract No.1054.
42.
Michaelis LC, Shafer D, Barton K, Rodriguez T, Smith S, Stiff P: Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease. Blood. 2009, 114: Abstract No.1034.
43.
Blum W, Klisovic R, Walker A, Garzon R, Liu S, Schaaf L: Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood. 2009, 114: Abstract No.2065.
44.
Silverman LR, Verma A, Odchimar-Reissig R, LeBlanc A, Najfeld V, Gabrilove J: A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium. ASH Annual Meeting Abstracts. 2008, 112: 3656-
45.
Ravandi F, Kantarjian H, Cripe L, Maris M, Cooper M, Dakhil S: A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 2009, 114: Abstract No.1037.
46.
Erba HP, O'Donnell M, Allen S, Baer M, Powell B, Stone R: Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study. Blood. 2009, 114: Abstract No.1047.
47.
Kyo T, Kimura A, Kyo K, Yoshida N, Asaoku H, Iwato K: High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care. Blood. 2009, 114: Abstract No.1052.
48.
Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P: Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009, 2: 20-10.1186/1756-8722-2-20.PubMedCentralCrossRefPubMed
49.
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B: Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009, 2: 36-10.1186/1756-8722-2-36.PubMedCentralCrossRefPubMed
50.
Ades L, Stamatoullas A, Raffoux E, Prebet T, Lenain P, Guieze R: Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study. Blood. 2009, 114: Abstract No.1049.
51.
Assouline SE, Cocolakis E, Rousseau C, Culjkovic B, Beslu N, Amri A: Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. Blood. 2009, 114: 10.1182/blood-2009-02-205153. Abstract No.2085.
52.
Garcia-Manero G, Khoury J, Borthakur G, Ravandi F, Kadia T, Estrov Z: A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias. Blood. 2009, 114: Abstract No.2047.
53.
Lowenberg B, Rousselot P, Martinelli G, Goudie A, Stockman P, Kantarjian H: Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD in Patients with Advanced Acute Myeloid Leukemia. Blood. 1152, 114: Abstract No.2080.
54.
Fremin C, Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Journal of Hematology & Oncology. 2010, 3: 8-10.1186/1756-8722-3-8.CrossRef
55.
Tai YT, Kim K, Li XF, Fulciniti M, Song W, Nahar S: Targeting MEK1/2 Signaling Cascade by AS70 a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo. ASH Annual Meeting Abstracts. 2009, 114: 3848-
56.
Odenike O, Curran E, Iyengar N, Popplewell L, Kirschbaum M, Erba H: Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML). Blood. 2009, 114: Abstract No.2081.
57.
Tibes R, McDonagh K, Lekakis L, Frazer N, Mohrland S, Dawn B: Phase I Study of the Novel Survivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias. Blood. 2009, 114: Abstract No.1039.
Metadata
Title
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
Authors
Xiongpeng Zhu
Yuehua Ma
Delong Liu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2010
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-3-17

Other articles of this Issue 1/2010

Journal of Hematology & Oncology 1/2010 Go to the issue

Short report

Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy?

Letter to the Editor

Analysis of Gγ-158(C→T) polymorphism in hemoglobin E/β-thalassemia major in Southern China

Research

CyberKnife® enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures

Letter to the Editor

Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia

Research

Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia

Case report

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits